Literature DB >> 11827925

Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings.

Emily Lubien1, Anthony DeMaria, Padma Krishnaswamy, Paul Clopton, Jen Koon, Radmila Kazanegra, Nancy Gardetto, Erin Wanner, Alan S Maisel.   

Abstract

BACKGROUND: Although Doppler echocardiography has been used to identify abnormal left ventricular (LV) diastolic filling dynamics, inherent limitations suggest the need for additional measures of diastolic dysfunction. Because data suggest that B-natriuretic peptide (BNP) partially reflects ventricular pressure, we hypothesized that BNP levels could predict diastolic abnormalities in patients with normal systolic function. METHODS AND
RESULTS: We studied 294 patients referred for echocardiography to evaluate ventricular function. Patients with abnormal systolic function were excluded. Cardiologists making the assessment of LV function were blinded to BNP levels. Patients were classified as normal, impaired relaxation, pseudonormal, and restrictivelike filling patterns. Patients diagnosed with evidence of abnormal LV diastolic function (n=119) had a mean BNP concentration of 286 +/- 31 pg/mL; those in the normal LV group (n=175) had a mean BNP concentration of 33 +/- 3 pg/mL. Patients with restrictive like filling patterns on echocardiography had the highest BNP levels (408 +/- 66 pg/mL), and patients with symptoms had higher BNP levels in all diastolic filling patterns. The area under the receiver-operating characteristic curve for BNP to detect any diastolic dysfunction was 0.92 (95% CI, 0.87 to 0.95; P<0.001). A BNP value of 62 pg/mL had a sensitivity of 85%, a specificity of 83%, and an accuracy of 84% for detecting diastolic dysfunction.
CONCLUSIONS: A rapid assay for BNP can reliably detect the presence of diastolic abnormalities on echocardiography. In patients with normal systolic function, elevated BNP levels and diastolic filling abnormalities might help to reinforce the diagnosis diastolic dysfunction.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11827925     DOI: 10.1161/hc0502.103010

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  133 in total

1.  The diagnostic accuracy and utility of a B-type natriuretic peptide test in a community population of patients with suspected heart failure.

Authors:  Ahmet Fuat; Jeremy J Murphy; A Pali S Hungin; Jane Curry; Ali A Mehrzad; Andrew Hetherington; Jennifer I Johnston; W Stuart A Smellie; Victoria Duffy; Patricia Cawley
Journal:  Br J Gen Pract       Date:  2006-05       Impact factor: 5.386

2.  Echocardiographic features and brain natriuretic peptides in patients presenting with heart failure and preserved systolic function.

Authors:  M D Thomas; K F Fox; D A Wood; J S R Gibbs; A J S Coats; M Y Henein; P A Poole-Wilson; G C Sutton
Journal:  Heart       Date:  2005-09-13       Impact factor: 5.994

3.  B-type natriuretic peptide and weaning from mechanical ventilation.

Authors:  Armand Mekontso-Dessap; Nicolas de Prost; Emmanuelle Girou; François Braconnier; François Lemaire; Christian Brun-Buisson; Laurent Brochard
Journal:  Intensive Care Med       Date:  2006-08-29       Impact factor: 17.440

4.  QRS and QTc interval prolongation in the prediction of long-term mortality of patients with acute destabilised heart failure.

Authors:  Tobias Breidthardt; Michael Christ; Miriam Matti; Delia Schrafl; Kirsten Laule; Markus Noveanu; Tujana Boldanova; Theresia Klima; Willibald Hochholzer; André P Perruchoud; Christian Mueller
Journal:  Heart       Date:  2007-03-29       Impact factor: 5.994

5.  Effect of aldosterone antagonism on exercise tolerance, Doppler diastolic function, and quality of life in older women with diastolic heart failure.

Authors:  Kurt R Daniel; Gretchen Wells; Kathryn Stewart; Brian Moore; Dalane W Kitzman
Journal:  Congest Heart Fail       Date:  2009 Mar-Apr

6.  Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction.

Authors:  Lisa C Costello-Boerrigter; Guido Boerrigter; Margaret M Redfield; Richard J Rodeheffer; Lynn H Urban; Douglas W Mahoney; Steven J Jacobsen; Denise M Heublein; John C Burnett
Journal:  J Am Coll Cardiol       Date:  2006-01-04       Impact factor: 24.094

7.  Effects of cigarette smoking on heart rate variability and plasma N-terminal pro-B-type natriuretic peptide in healthy subjects: is there the relationship between both markers?

Authors:  Omer Alyan; Fehmi Kacmaz; Ozcan Ozdemir; Orhan Maden; Serkan Topaloglu; Cemal Ozbakir; Fatma Metin; Aziz Karadede; Erdogan Ilkay
Journal:  Ann Noninvasive Electrocardiol       Date:  2008-04       Impact factor: 1.468

8.  Are levels of NT-proBNP and SDMA useful to determine diastolic dysfunction in chronic kidney disease and renal transplant patients?

Authors:  Lidija Memon; Vesna Spasojevic-Kalimanovska; Natasa Bogavac Stanojevic; Jelena Kotur-Stevuljevic; Sanja Simic-Ogrizovic; Vojislav Giga; Violeta Dopsaj; Zorana Jelic-Ivanovic; Slavica Spasic
Journal:  J Clin Lab Anal       Date:  2013-11       Impact factor: 2.352

9.  Isolated diastolic dysfunction--diagnostic value of tissue Doppler imaging, colour M-mode and N-terminal pro B-type natriuretic peptide.

Authors:  S Hettwer; B Panzner-Grote; R Witthaut; K Werdan
Journal:  Clin Res Cardiol       Date:  2007-09-20       Impact factor: 5.460

10.  Reduced diurnal variation of heart rate is associated with increased plasma B-type natriuretic peptide level in patients with atrial fibrillation.

Authors:  Shigeshi Kamikawa; Toru Miyoshi; Masayuki Doi; Naoko Orita; Mutsuko Sangawa; Takaaki Nakatsu; Youko Noguchi; Satoshi Hirohata; Shozo Kusachi; Kazufumi Nakamura; Hiroshi Ito
Journal:  Clin Cardiol       Date:  2013-04-12       Impact factor: 2.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.